chartexchange

Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat

GlobeNewswire Inc. | Nov 17, 2026 6:40 PM EST

ERAS-0015 will be evaluated with PRMT5 inhibitor navlimetostat in MTAP-deleted pancreatic cancer in Phase 1/2 trial

Read original article